Pharmacological Management of Hypertension in Type 2 Diabetic Patients: Drug Selection, Treatment Guidelines, Interactions, and Safety

Abstract

Hypertension and type 2 diabetes mellitus (T2DM) are among the most prevalent chronic conditions worldwide and commonly coexist in the same patient. The simultaneous presence of these two conditions significantly amplifies the risk of cardiovascular, renal, and cerebrovascular complications. Optimal pharmacological management of hypertension in diabetic patients requires careful drug selection that not only controls blood pressure but also confers cardiorenal protective benefits.  This literature review aims to evaluate the pharmacological classes used in managing hypertension in T2DM patients, analyze current treatment guidelines, assess drug-drug and drug-disease interactions, and highlight safety considerations critical for clinical practice. Methods: A comprehensive search of published literature was conducted using PubMed, MEDLINE, and Google Scholar databases. Studies, clinical trial reports, and established treatment guidelines from the American Diabetes Association (ADA), Joint National Committee (JNC 8), and the European Society of Cardiology (ESC) were reviewed and synthesized. Conclusions: ACE inhibitors and ARBs remain the first-line agents of choice in hypertensive T2DM patients, particularly in those with proteinuria or diabetic nephropathy, owing to their proven renoprotective and cardioprotective properties. Combination therapy is frequently required to achieve target blood pressure goals, but must be approached with vigilance to avoid nephrotoxic combinations and electrolyte imbalances. Individualized pharmacological management guided by comorbidities, organ function, and drug interaction profiles is essential.